In this month's newsletter ..
- Navigate to curated resources on psoriasis for psoriasis awareness month
- Read about how Cencora participated in the recent ATOPP Summit and ThoughtSpot 2024
- Access the latest eDossiers available
- Register for the upcoming AMCP webinar hosted by FormularyDecisions on AI
August is Psoriasis Awareness Month
The prevalence of psoriasis among US adults aged 20 years or older is approximately 0.3% (7.5 million adults).1 There are 16 biologics2 currently available for the treatment of psoriasis and/or psoriatic arthritis, 2 of which were selected for the first round of price negotiations as part of the Inflation Reduction Act (IRA).3
Due to the increase in the number and cost of these specialty medications, it is important for healthcare decision makers to have relevant and timely product information to manage costs while still facilitating medication access to patients.
Check out the Biosimilar Hub to view the current pipeline and market landscape for psoriasis and psoriatic arthritis products. Easily look up phases and launch dates for each product on the landscape overview.
Reference available Product Snapshots on products for psoriasis. Product Snapshots, curated by clinical pharmacists at ForHealth Consulting team at UMass Chan Medical School, not only provide a high-level overview of the product, but they also include a summary of key clinical trials and Pharmacy & Therapeutics considerations.
Leverage the Metasearch Results across different psoriasis disease and product pages where you can find a number of articles from credible resources and publications such as PubMed, Journal of Managed Care & Specialty Pharmacy, Pharmacist’s Letter, and more.
While the Metasearch Results provides an extensive catalog of articles, here is a sample list of articles available on the psoriasis disease page:
- Chronic plaque psoriasis in adults: Overview of management
- Cardiovascular effects of psoriasis: The importance of making the connection
- Racial/ethnic differences in autoimmune disease prevalence in US claims/EHR data
- Classifying patients with psoriatic arthritis according to their disease activity status using serum metabolites and machine learning
This announcement is an advertisement paid for by IntraBio. FormularyDecisions is not providing a product recommendation. Readers should review all available materials related to the product and indication discussed herein before making any decision related to the purchase or use of the product. Any questions about such products must be directed to the biopharma company. The availability of this product information follows the guidance outlined in the Pre-approval Information Exchange Act of 2022 (Section 810 of H.R. 7667).
Connecting at conferences
Cencora team members have been busy this summer, attending Advanced Topics for Oncology Pharmacy Professionals (ATOPP) Summit in St. Louis and ThoughtSpot 2024 in Orlando.
ATOPP Summit
At ATOPP Summit, we connected with oncology and hematology professionals in a collaborative effort to learn about and help address barriers to patient access.
Based on our conversations with attendees, additional resources will be added to the Cell & Gene Therapy Hub on FormularyDecisions as we continue to evolve the tool to meet the product information needs of healthcare decision makers.
Based on our conversations with attendees, additional resources will be added to the Cell & Gene Therapy Hub on FormularyDecisions as we continue to evolve the tool to meet the product information needs of healthcare decision makers.
Cencora team members from left to right: Molly Bray, MBA; Savannah Scary; Ben Pennell, PharmD, MS; Chara Reed, PharmD; Lakesha Farmer, PharmD, MBA; Cynthia Thai, PharmD
ThoughtSpot 2024
At ThoughtSpot 2024, Tasmina Hydery, PharmD, MBA, BCGP, and Nick Howard, PharmD, presented a continuing education session titled “Old Bugs, New Tricks: The Latest on Vaccines, Immunization Schedules, and Community Health.” ThoughtSpot is an annual conference and trade show organized by Good Neighbor Pharmacy and Cencora, catering to independent community pharmacies and long-term care pharmacies.
The session covered new prevention methods and pipeline agents, recent guideline updates, vaccine administration practices, strategies for integrating vaccine education within community pharmacies, and the role of community pharmacists in addressing health inequities. It also highlighted how community pharmacists continue to play a crucial part in advancing public health through vaccination by implementing best practices for vaccine education and tackling health disparities within their communities.
The session covered new prevention methods and pipeline agents, recent guideline updates, vaccine administration practices, strategies for integrating vaccine education within community pharmacies, and the role of community pharmacists in addressing health inequities. It also highlighted how community pharmacists continue to play a crucial part in advancing public health through vaccination by implementing best practices for vaccine education and tackling health disparities within their communities.
Cencora team members from left to right: Tasmina Hydery, PharmD, MBA, BCGP and Nick Howard, PharmD
New and updated eDossiers
Did you know that the eDossier PDF viewer includes a user-friendly table of contents for seamless navigation, as well as tools for annotation that are included in eDossier exports? Explore all these features and more in this 2-minute video tutorial.
Leverage the innovative tools from the video tutorial to help you navigate eDossiers like a pro. See below for links to the product pages with eDossiers that were posted or updated within the last 90 days. On any product page, you have the option to access the specific eDossiers by submitting an eRequest.
Log into FormularyDecisions today to view all eDossiers available.
PDUFA date |
Pipelinea product name |
|
8/22/2024 |
|
|
9/24/2024 |
|
|
9/26/2024 |
|
|
11/29/2024 |
|
|
03/26/2025 |
|
|
NAb |
Product name |
FDA approval date* |
FDA-approved indicationc |
|
09/06/2023 |
MCC, RCC, UC |
|
|
04/30/2009 |
Exocrine pancreatic insufficiency |
|
|
03/10/2023 |
Rett syndrome |
|
|
12/23/2019 |
Insomnia |
|
|
06/20/2024 |
DMDd |
|
|
05/09/2023 |
Fabry disease |
|
|
07/03/2008 |
Contrast agent for use with MRI |
|
|
07/12/2019 |
Contrast agent for use with MRI |
|
|
04/21/2020 |
MCL,d CLL, SLL, WM, MZL,d cGVHD |
|
|
06/10/2024 |
RA, PMR, pJIA |
|
|
06/17/2024 |
Melanoma, NSCLC, HNSCC, cHL,d PMBCL,d urothelial cancer, MSI-H or dMMR, CRC, gastric cancer, esophageal cancer, cervical cancer, HCC, BTC, MCC, RCC, endometrial carcinoma, TMB-H cancer, cSCC, TNBC |
|
|
08/03/2017 |
HCV |
|
|
NEXLETOL® (bempedoic acid)16and NEXLIZET® (bempedoic acid and ezetimibe)17 |
03/22/2024 |
Hyperlipidemia |
|
11/27/2023 |
Desmoid tumors |
|
|
12/15/2023 |
la/mUC |
|
|
05/25/2023 |
COVID-19 |
|
|
10/20/2023 |
Meningococcal disease |
|
|
03/14/2024 |
NASHd |
|
|
07/29/2022 |
PsO, PsA, CD, UC |
|
|
02/15/2024 |
NSCLC |
|
|
04/29/2024 |
Cervical cancer |
|
|
08/02/2019 |
TGCT |
|
|
01/10/2020 |
epilepsy |
|
|
07/20/2023 |
AML |
|
|
01/19/2021 |
HF |
|
|
08/26/2022 |
CIC |
|
|
03/26/2024 |
PAH (WHO Group 1) |
*For multi-indication products, the FDA-approved date for the most recent approved indication is listed.
Key: AML – acute myeloid leukemia; BTC – biliary tract cancer; CD – Crohn’s disease; cGVHD – chronic graft versus host disease; cHL – classical Hodgkin lymphoma; CIC: chronic idiopathic constipation; CLL – chronic lymphocytic leukemia; CRC – colorectal cancer; cSCC – cutaneous squamous cell carcinoma; DMD – Duchenne muscular dystrophy; dMMR –mismatch repair deficient; HAE – hereditary angioedema; HCC – hepatocellular carcinoma; HCV – hepatitis C virus; HF – heart failure; HNSCC – head and neck squamous cell cancer; la/mUC – locally advanced or metastatic urothelial carcinoma; MCC – Merkel cell carcinoma; MCL – mantle cell lymphoma; MRI – magnetic resonance imaging; MSI-H – microsatellite instability-high; MZL – marginal zone lymphoma; NASH – noncirrhotic nonalcoholic steatohepatitis; NSCLC – non-small cell lunch cancer; PAH – pulmonary arterial hypertension; pJIA – polyarticular juvenile idiopathic arthritis; PMBCL – primary mediastinal large B-cell lymphoma; PMR – polymyalgia rheumatica; PsA – psoriatic arthritis; PsO – plaque psoriasis; RA – rheumatoid arthritis; RCC – renal cell carcinoma; SLL – small lymphocytic lymphoma; TGCT – tenosynovial giant cell tumor; TNBC – triple-negative breast cancer; TMB-H – tumor mutational burden-high; UC – ulcerative colitis; WHO – World Health Organization; WM – Waldenström’s macroglobulinemia.
Upcoming Webinar(s)
AMCP Webinar hosted by FormularyDecisions
Session: Harnessing the Power of AI in Health Evidence Generation Strategy
Date: Tuesday, Sept 17, 2024
Time: 2:00-3:00pm ET
Join this interactive session where we will review insights from healthcare decision makers on AI adoption within their organizations. Additionally, our expert panelists will explore opportunities to mitigate concerns about AI acceptance and hesitation in today’s complex landscape. Using real-world case studies, we will also share how AI can be used to improve efficiencies in aggregating data and communicating evidence.
Click below for webinar details and to register through the AMCP website
Time: 2:00-3:00pm ET
Join this interactive session where we will review insights from healthcare decision makers on AI adoption within their organizations. Additionally, our expert panelists will explore opportunities to mitigate concerns about AI acceptance and hesitation in today’s complex landscape. Using real-world case studies, we will also share how AI can be used to improve efficiencies in aggregating data and communicating evidence.
Learning objectives:
- Review market research insights on AI adoption and perceptions among healthcare decision makers.
- Examine current capabilities and limitations of AI-powered tools.
- Identify best practices for the practical application of AI in health evidence generation strategy.
- Discuss trends and future opportunities to accelerate the trajectory of AI in an evolving landscape.
Click below for webinar details and to register through the AMCP website
